Less Ads, More Data, More Tools Register for FREE

LONDON BROKER RATINGS: Berenberg raises Vodafone; Barclays cuts Hikma

Wed, 07th Jan 2026 10:04

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

----------

FTSE 100

----------

Berenberg raises Vodafone to 'buy' (hold) - price target 119 (82) pence

----------

Morgan Stanley raises Rentokil Initial to 'overweight' (equal weight) - price target 520 (450) pence

----------

Morgan Stanley cuts DCC to 'equal weight' (overweight) - price target 5,750 (6,150) pence

----------

Morgan Stanley raises Ashtead price target to 6,200 (6,000) pence - 'overweight'

----------

Barclays reinitiates GSK with 'underweight' - price target 1,780 pence

----------

Barclays raises AstraZeneca price target to 16,500 (14,000) pence - 'overweight'

----------

Barclays cuts Hikma Pharmaceuticals to 'underweight' (equal weight) - price target 1,600 (2100) pence

----------

Bernstein cuts Unilever price target to 5,800 (5,900) pence - 'outperform'

----------

Jefferies raises Unilever price target to 4,100 (4,000) pence - 'underperform'

----------

Bernstein raises Reckitt Benckiser price target to 7,500 (6,500) pence - 'outperform'

----------

Jefferies raises Reckitt Benckiser price target to 5,900 (5,500) pence - 'hold'

----------

Bernstein cuts Haleon price target to 415 (420) pence - 'market-perform'

----------

Berenberg raises Next price target to 18,000 (17,800) pence - 'buy'

----------

Barclays raises Next price target to 13,700 (13,400) pence - 'equal weight'

----------

Citigroup cuts Whitbread price target to 3,100 (3,800) pence - 'buy'

----------

Citigroup raises J Sainsbury price target to 366 (349) pence - 'buy'

----------

Citigroup raises Tesco price target to 515 (510) pence - 'buy'

----------

Deutsche Bank Research raises Admiral price target to 3,550 (3,500) pence - 'buy'

----------

Deutsche Bank Research cuts Phoenix Group to 'hold' (buy) - price target 755 (720) pence

----------

Deutsche Bank Research reinitiates Aviva with 'buy' - price target 760 pence

----------

Deutsche Bank Research reinitiates Prudential with 'buy' - price target 1,355 pence

----------

Deutsche Bank reinitiates Legal & General with 'hold' - price target 270 pence

----------

Deutsche Bank Research reinitiates M&G with 'hold' - price target 290 pence

----------

Deutsche Bank Research raises Beazley price target to 1,050 (977) pence - 'buy'

----------

UBS cuts Diageo price target to 1,780 (1,850) pence - 'neutral'

----------

FTSE 250

----------

Morgan Stanley raises RS to 'overweight' (equal weight) - price target 790 pence

----------

Jefferies raises Drax price target to 1,120 (750) pence - 'buy'

----------

Deutsche Bank Research raises Applied Nutrition price target to 295 (235) pence - 'buy'

----------

Deutsche Bank Research cuts Aston Martin price target to 75 (80) pence - 'hold'

----------

SMALL CAP

----------

Barclays cuts Wise price target to 1,130 (1,250) pence - 'overweight'

----------

Deutsche Bank Research raises Sabre Insurance price target to 190 (183) pence - 'buy'

----------

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Vodafone Rentokil Initial DCC Glaxosmithkline Astrazeneca Hikma Pharmaceuticals Unilever Reckitt Haleon Next Whitbread Sainsbury's Tesco Admiral Aviva Prudential Legal & General M&G Beazley Diageo Drax Applied Nutrition PLC Aston Martin Lagonda Wise Group Sabre Insurance Group

Shares in this article

Related News

EARNINGS AND TRADING: Everplay pushes back Hell Let Loose release date
8 hours ago

EARNINGS AND TRADING: Everplay pushes back Hell Let Loose release date

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

AstraZeneca breast cancer drug camizestrant shows "sustained" benefit
17 hours ago

AstraZeneca breast cancer drug camizestrant shows "sustained" benefit

(Alliance News) - AstraZeneca PLC on Tuesday reported encouraging test results for its breast cancer treatment camizestrant.

BSF Enterprise shares jump on paper in praise of "T-rex leather"
19 hours ago

BSF Enterprise shares jump on paper in praise of "T-rex leather"

(Alliance News) - BSF Enterprise on Tuesday saw its shares rise after the publication of a paper on one of its subsidiaries' synthetic leather product...